Statins have revolutionized cardiovascular disease prevention by helping lower "bad" cholesterol or L-D-L levels in the blood. However, even with lower L-D-L levels many patients are at risk for experiencing heart attack, stroke and other complications. Raising H-D-L or "good" cholesterol levels can help in reducing these risks but finding the right medication to do this has been challenging. A new study that tested an experimental medication from a different class of drugs has promising results. Catherine Dolf explains in this week's JAMA Report.